Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mk-2461. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET known ✓ | P08581 | 20/20 | 1.00 |
| ▸ | MST1R | Q04912 | 2/20 | 1.00 |
| ▸ | AURKA | O14965 | 1/20 | 1.00 |
| ▸ | JAK2 | O60674 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | NTRK1 | P04629 | 1/20 | 1.00 |
| ▸ | RET | P07949 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 1/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | NQO2 | P16083 | 1/20 | 1.00 |
| ▸ | FLT1 | P17948 | 1/20 | 1.00 |
| ▸ | FGFR2 | P21802 | 1/20 | 1.00 |
| ▸ | FGFR3 | P22607 | 1/20 | 1.00 |
| ▸ | FECH | P22830 | 1/20 | 1.00 |
| ▸ | FLT4 | P35916 | 1/20 | 1.00 |
| ▸ | KDR | P35968 | 1/20 | 1.00 |
| ▸ | FLT3 | P36888 | 1/20 | 1.00 |
| ▸ | MAPK9 | P45984 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mk-2461 SCHEMBL29356324 | 1.00 | MET (1.00) | METMST1RAURKAJAK2ABL1 | |
| Mk-2461 SCHEMBL2326906 | 1.00 | MET (1.00) | METMST1RAURKAJAK2ABL1 | |
| Mk-2461 SCHEMBL29529144 | 1.00 | MET (1.00) | METMST1RAURKAJAK2ABL1 | |
| Mk-2461 SCHEMBL2326614 | 1.00 | MET (1.00) | METMST1RAURKAJAK2ABL1 | |
| Mk-2461 SCHEMBL93526 | 1.00 | MET (1.00) | METMST1RAURKAJAK2ABL1 | |
| Mk-2461 SCHEMBL1269865 | 0.99 | MET (0.98) | METMST1RAURKAJAK2ABL1 | |
| Mk-2461 SCHEMBL1270766 | 0.99 | MET (0.98) | METMST1RAURKAJAK2ABL1 | |
| Mk-2461 SCHEMBL1269863 | 0.99 | MET (0.98) | METMST1RAURKAJAK2ABL1 | |
| Mk-2461 SCHEMBL1270764 | 0.99 | MET (0.98) | METMST1RAURKAJAK2ABL1 | |
| SCHEMBL4316174 | 0.92 | MET (0.84) | METMST1RAURKAJAK2ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026102277-A1 | COMBINATION THERAPIES COMPRISING IKZF2 DEGRADER COMPOUNDS | Plexium, Inc. (US) | 2026-05-15 | — | — | WO | disclosed |
| EP-4562010-A1 | CRYSTALLINE FORMS OF AN AKR1C3 DEPENDENT KARS INHIBITOR | Novartis AG (CH) | 2025-06-04 | — | — | EP | disclosed |
| EP-4323526-A1 | ANTIBODY DRUG CONJUGATES AND METHODS FOR MAKING THEREOF | Novartis AG (CH) | 2024-02-21 | — | — | EP | disclosed |
| EP-4320150-A1 | USES OF ANTI-TGF BETA ANTIBODIES AND OTHER THERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis AG (CH) | 2024-02-14 | — | — | EP | disclosed |
| WO-2024023666-A1 | CRYSTALLINE FORMS OF AN AKR1C3 DEPENDENT KARS INHIBITOR | NOVARTIS AG (CH) | 2024-02-01 | — | — | WO | disclosed |
| WO-2023214325-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AND USES THEREOF AS TET2 INHIBITORS | NOVARTIS AG (CH) | 2023-11-09 | — | — | WO | disclosed |
| EP-3296905-B1 | METHOD FOR IDENTIFYING NEW MARKERS | ALACRIS THERANOSTICS GMBH (DE) | 2023-11-08 | — | — | EP | disclosed |
| EP-4204020-A1 | METHOD OF TREATING PSMA-EXPRESSING CANCERS | Advanced Accelerator Applications International S.A. (CH) | 2023-07-05 | — | — | EP | disclosed |
| EP-4168007-A1 | DOSING REGIMEN COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES | Novartis AG (CH) | 2023-04-26 | — | — | EP | disclosed |
| EP-4142799-A1 | CCR7 ANTIBODY DRUG CONJUGATES FOR TREATING CANCER | Novartis AG (CH) | 2023-03-08 | — | — | EP | disclosed |
| EP-4107279-A1 | METHOD OF TREATING PSMA-EXPRESSING CANCERS | Endocyte, Inc. (US) | 2022-12-28 | — | — | EP | disclosed |
| WO-2022243846-A1 | COMBINATION THERAPIES | NOVARTIS AG (CH) | 2022-11-24 | — | — | WO | disclosed |
| EP-4076660-A1 | USES OF ANTI-TGF-BETA ANTIBODIES AND CHECKPOINT INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis AG (CH) | 2022-10-26 | — | — | EP | disclosed |
| WO-2022221720-A1 | ANTIBODY DRUG CONJUGATES AND METHODS FOR MAKING THEREOF | NOVARTIS AG (CH) | 2022-10-20 | — | — | WO | disclosed |
| WO-2022215011-A1 | USES OF ANTI-TGFβ ANTIBODIES AND OTHER THERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2022-10-13 | — | — | WO | disclosed |
| EP-4007592-A1 | ANGIOTENSIN TYPE 2 (AT2) RECEPTOR AGONISTS FOR USE IN THE TREATMENT OF CANCER | LanthioPep B.V. (NL) | 2022-06-08 | — | — | EP | disclosed |
| WO-2022043558-A1 | METHOD OF TREATING PSMA-EXPRESSING CANCERS | ADVANCED ACCELERATOR APPLICATIONS INTERNATIONAL SA (CH) | 2022-03-03 | — | — | WO | disclosed |
| WO-2022043556-A1 | STABLE RADIOPHARMACEUTICAL COMPOSITION | NOVARTIS AG (CH) | 2022-03-03 | — | — | WO | disclosed |
| WO-2022043557-A1 | METHOD OF TREATING PSMA-EXPRESSING CANCERS | ADVANCED ACCELERATOR APPLICATIONS INTERNATIONAL SA (CH) | 2022-03-03 | — | — | WO | disclosed |